We believe that our novel treatment approach, Epimacular Brachytherapy, greatly reduces the number of anti-VEGF injections, while maintaining visual acuity – especially in those lesion subtypes that typically require a large number of injections.
Newark, CA (PRWEB) July 11, 2011
NeoVista, Inc. announced today the first commercial utilization of Epimacular Brachytherapy in Switzerland. Epimacular Brachytherapy is performed using the VIDION ANV Therapy system and is being offered as an adjunct therapy to anti-VEGF injections for the treatment of neovascular or wet age-related macular degeneration.
John N. Hendrick, President and CEO of NeoVista commented, “Today is an extraordinary day for NeoVista, our local business partner, OctreoPharm Vertriebs GmbH, and the multitude of patients who suffer from this debilitating and life-altering disease. The burden of wet AMD to those afflicted with the disease, and their caregivers, is enormous.”
Professor Dr. Marc D. de Smet, Professor and Head of the Retina Unit at the Montchoisi Clinic in Lausanne stated, "Epimacular Brachytherapy with VIDION® is a surgical procedure that is technically feasible in good hands, with minimal to no risks and reduces the burden of follow up and retreatments.”
Mr. Hendrick added, “NeoVista’s phase 2 clinical study results continue to highlight the potential benefits of utilizing radiation with anti-VEGF therapy in treating wet AMD – especially on smaller classic lesions and patients with pigment epithelial detachments. We believe that our novel treatment approach, Epimacular Brachytherapy, greatly reduces the number of anti-VEGF injections, while maintaining visual acuity – especially in those lesion subtypes that typically require a large number of injections."
NeoVista’s Phase 3 study, CABERNET, is about to conclude the required 2 year patient follow-up. The initial data from this landmark study is scheduled to be presented during the upcoming AAO Retina Sub-Specialty Meeting in Orlando, Florida, October 21. The NeoVista approach to treating wet AMD delivers a focused and fixed dose of strontium 90 beta radiation directly to the back of the eye, without damaging the adjacent healthy retinal vasculature. Importantly for patients, the systemic exposure to radiation is easily tolerated and the energy is delivered in a highly controlled manner to a local area. The effective dose from this one-time treatment is less than that from a typical chest x-ray to the entire body.
About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Newark, California. For more information about the company, or this novel therapy, please visit the company's Web site at http://www.neovistainc.com.